Mannitol in Ischemic Stroke: Limited Role as Temporizing Measure Only

Primary Indication: Threatened Herniation Only

The American Heart Association recommends mannitol for reduction of intracranial pressure and brain mass in ischemic stroke patients with clinical evidence of threatened intracranial hypertension or signs of brain herniation, such as pupillary abnormalities, decerebrate posturing, or neurological deterioration with documented midline shift or mass effect 1, 2
Mannitol is indicated for patients with documented elevated intracranial pressure, used only as a bridge to definitive surgical decompression—not as routine therapy 1, 2, 3

The American Heart Association guidelines specify a dosing range of 0.25 to 0.5 g/kg IV over 20 minutes, which can be repeated every 6 hours as needed, with evidence showing smaller doses (0.25 g/kg) are as effective as larger doses (0.5-1 g/kg) for acute ICP reduction 2
The maximum total daily dose is 2 g/kg, and mannitol should be discontinued when serum osmolality exceeds 320 mOsm/L 2, 3

There is insufficient data to recommend mannitol as a preemptive measure in patients with early CT swelling, and the American Heart Association/American Stroke Association explicitly states that prophylactic use is not supported 1

The most appropriate use of mannitol is as a temporizing measure before decompressive craniectomy for large hemispheric infarcts with malignant edema, and mannitol should only be used to buy time until surgery can be performed 2, 5, 3

Hypertonic saline (3% or 23.4%) is an alternative osmotic agent with comparable efficacy to mannitol at equiosmolar doses, and should be chosen over mannitol when hypovolemia or hypotension is present, or when a longer duration of action is desired 2, 5

The most common error is prophylactic or routine use of mannitol in ischemic stroke without documented elevated ICP or clinical herniation signs, which is not supported by evidence and may increase mortality 1, 3